Uncategorized

Carbon Engineering

Carbon Engineering has been acquired by Occidental Petroleum (NYSE: OXY) in a $1.1B all cash transaction.

Bango

Bango (AIM:BGO) announced the acquisition of Docomo Digital – the global payments business of NTT DOCOMO – bringing an additional $3.5B of end user spend from c.2 billion users worldwide.

Phico Therapeutics

Phico Therapeutics awarded up to $18.2 million (c.£13.2 million) CARB-X funding to advance SASPject antibacterial therapy through Phase 1 clinical trials.

ADC Therapeutics

FDA approves first ADC Therapeutics anti-cancer drug, ZYNLONTA™, for clinical use in patients with relapsed or refractory diffuse large B-Cell Lymphoma.

Carbon13

ET Capital, in collaboration with Carbon13 – the venture builder for the climate emergency, has launched the first of a series of SEIS funds investing in new businesses focused on signficant carbon emission reduction.

ADC Therapeutics

ADC Therapeutics SA, the innovative anti-cancer therapeutics business, has floated on the New York Stock Exchange. Demand for the issue was high with an upsized placing and shares trading at an immediate premium.

ADC Therapeutics

ADC Therapuetics announces positive results from pivotal Phase 2 clinical trial of its lead therapeutic.

Oxsight

BBC features the life transforming impact of Oxsight Crystal smart glasses for a patient with Usher’s disease.

ADC Therapeutics

ADC Therapeutics Announces First Patients Dosed in Phase I/II Clinical Trial of ADCT-602 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

Phico Therapeutics

Phico Therapeutics awarded Innovate UK funding for £1.4 million ($1.87M) antibacterial therapy project.